Comprehensive medication guide to Descovy including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
Most insurance plans cover Descovy for PrEP at $0 cost sharing under ACA preventive services, though some plans may require step therapy with generic Truvada first.
Estimated Cash Pricing
Descovy costs between $2,200 and $2,944 per month (30 tablets) without insurance.
Medfinder Findability Score
65/100
Summarize with AI
On this page
Descovy is a prescription medication made by Gilead Sciences that contains two nucleoside reverse transcriptase inhibitors (NRTIs): emtricitabine and tenofovir alafenamide (TAF). It is FDA-approved for two main uses:
Descovy uses tenofovir alafenamide (TAF), a newer and more targeted form of tenofovir compared to the older tenofovir disoproxil fumarate (TDF) found in Truvada, offering improved kidney and bone safety profiles.
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
Descovy works by combining two NRTIs that block HIV from replicating inside the body:
TAF achieves high antiviral concentrations inside cells at a dose roughly 10 times lower than the older tenofovir disoproxil fumarate (TDF), which results in lower systemic tenofovir levels and improved renal and bone safety. When taken daily, Descovy either suppresses HIV viral load (for treatment) or prevents HIV from establishing infection (for PrEP).
200 mg Emtricitabine / 25 mg Tenofovir Alafenamide
film-coated tablet for adults and adolescents weighing at least 35 kg
120 mg Emtricitabine / 15 mg Tenofovir Alafenamide
film-coated tablet for pediatric patients weighing 14 kg to less than 25 kg
Descovy scores a 65 out of 100 on our findability scale, placing it in the "intermittent issues" category. While Descovy is not currently listed on the FDA Drug Shortage database, it remains a brand-name-only medication with no FDA-approved generic available in the United States as of early 2026. This means supply is limited to a single manufacturer (Gilead Sciences), and the extremely high cash price of $2,200–$2,944 per month can create significant access barriers for uninsured or underinsured patients. Most well-stocked pharmacies carry Descovy, but smaller or independent pharmacies may not keep it on hand due to its cost and niche patient population.
Descovy can be prescribed by a range of healthcare providers, including:
Descovy is also available through telehealth services, making it easier to obtain a PrEP prescription without an in-person visit.
No, Descovy is not a controlled substance. It is not classified under any DEA schedule. Descovy is a standard prescription medication that requires a valid prescription from a licensed healthcare provider but does not carry the restrictions associated with controlled substances.
Serious side effects (less common but important to watch for):
Boxed Warning: Descovy carries FDA boxed warnings regarding the risk of drug-resistant HIV-1 if used for PrEP in individuals with undiagnosed HIV infection, and severe hepatitis B flares upon discontinuation in co-infected patients.
Know what you need? Skip the search.
Truvada (Emtricitabine/Tenofovir Disoproxil Fumarate)
The older NRTI combination for both HIV treatment and PrEP. Generic versions are widely available at $30–$100 per month, making it a significantly more affordable option. Unlike Descovy, generic Truvada is approved for all populations including individuals at risk from receptive vaginal sex.
Apretude (Cabotegravir Extended-Release Injectable)
A long-acting injectable PrEP option given every 2 months. Ideal for patients who struggle with daily pill adherence. Approved for adults and adolescents at risk of sexually acquired HIV-1.
Sunlenca/Lenacapavir (Yeztugo)
A newer long-acting injectable PrEP option given just twice yearly. FDA approved for PrEP in 2024–2025, offering the longest dosing interval currently available.
Prefer Descovy? We can find it.
P-glycoprotein (P-gp) inhibitors
moderatemay increase tenofovir alafenamide concentrations in the body
P-gp inducers
moderate(carbamazepine, oxcarbazepine, phenobarbital, phenytoin, rifampin, rifabutin, St. John's Wort) may decrease TAF levels and reduce Descovy's effectiveness
Drugs affecting renal function
moderate(acyclovir, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides, high-dose NSAIDs) may increase emtricitabine and tenofovir concentrations and the risk of side effects
Do not take with other medications containing emtricitabine or tenofovir
moderate, including Truvada, Atripla, Complera, Stribild, Genvoya, Odefsey, Symtuza, or Biktarvy
Descovy is a highly effective medication for both HIV treatment and HIV prevention (PrEP), offering improved kidney and bone safety compared to the older Truvada formulation. However, its high cash price of $2,200–$2,944 per month and lack of a US generic make affordability a significant concern. The good news is that most insurance plans cover Descovy for PrEP at $0 cost sharing under the ACA preventive services mandate, and Gilead's co-pay assistance program can cover up to $7,200 per year in out-of-pocket costs for commercially insured patients. Uninsured patients may qualify for Gilead's Patient Assistance Program, which provides Descovy at no cost. If you're having trouble finding or affording Descovy, Medfinder can help you locate pharmacies near you that have it in stock.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards